In a note to clients, Credit Suisse said its meeting with senior Pfizer executives boosted its confidence in both management and the prospects for new products.
The move follows Credit Suisse's recent stock-price upgrade on Pfizer, in which analyst Vamil Divan raised his 12-month price target to $48 while maintaining an outperform rating.
It also adds to a string of recent positive news for Pfizer.
At the end of April, the company reported stronger-than-expected first-quarter earnings and a boost to the mid-point of its full-year profit forecast amid strong demand for its pharma products.
And on May 6 it announced that it received U.S. Food and Drug Administration approval of its drug tafamidis for treatment of a rare form of heart disease.
Shares of Pfizer were up 0.41% to $41.32 in trading on the New York Stock Exchange.